A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
NCT00743509 is a phase 2 interventional trial sponsored by University of Michigan Rogel Cancer Center. As of 21 Nov 2026, it is completed. It studies Cyclophosphamide and Sirolimus in Osteosarcoma. The registry lists an enrollment of 49 participants at 1 site in 1 country. The registry lists a start date of 31 Aug 2008 and a primary completion date of 30 Apr 2010. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00743509 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | University of Michigan Rogel Cancer Center |
| Enrollment | 49 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Osteosarcoma |
| Drugs | Cyclophosphamide and Sirolimus |
| Start | 31 Aug 2008 |
| Primary completion | 30 Apr 2010 |
| Study completion | 30 Sept 2012 |
| Last update posted | 28 Sept 2015 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Scott Schuetze, MD, PhD
University of Michigan Rogel Cancer Center
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Michigan
Ann Arbor
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00743509
Each answer restates registry values shown on this page.
What is NCT00743509?
NCT00743509 is a phase 2 interventional trial sponsored by University of Michigan Rogel Cancer Center. It studies Cyclophosphamide and Sirolimus in Osteosarcoma.
Who leads NCT00743509?
The registry names Scott Schuetze, MD, PhD (principal investigator, University of Michigan Rogel Cancer Center) as the overall official.
Where does NCT00743509 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00743509 study?
The registered drug and biological interventions are Cyclophosphamide and Sirolimus.
When did NCT00743509 end?
The registry lists a primary completion date of 30 Apr 2010 and a study completion date of 30 Sept 2012. The sponsor last updated the record on 28 Sept 2015.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.